While the prevalence of blindness due to age-related macular degeneration decreased globally from 2000 to 2020, researchers warn that the social and economic impact of AMD may grow as the population ages.
“Developing novel, cost-effective treatment modalities ideally restoring sight, and adopting a life-course approach integrating all levels of care is paramount for managing AMD for the next decades,” researchers in the Vision Loss Expert Group of the Global Burden of Disease Study, wrote in Eye.
In a systemic review and meta-analysis of population-based surveys from January 1980 to